Completed PHASE2 INTERVENTIONAL 1-arm NCT00431769

An Efficacy and Safety Study of Bortezomib Re-treatment in Multiple Myeloma

A Phase II, Open-Label Trial Using Velcade for ReTreatment of Multiple Myeloma Subjects Following an Initial Response to Velcade

Sponsor: Janssen-Cilag International NV

Conditions Multiple Myeloma

Interventions Bortezomib

Updated 6 times since 2017 Last updated: May 9, 2014 Started: Jun 30, 2006 Primary completion: Feb 28, 2009 Completion: Jan 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Multiple Myeloma and is currently completed. Janssen-Cilag International NV leads this study, which shows 6 recorded versions since 2006 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jun 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Janssen-Cilag International NV

Data source: Janssen-Cilag International NV

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Almada, Portugal , Antwerp, Belgium , Athens, Greece , Bad Soden, Germany , Barcelona, Spain , Berlin, Germany , Brussels, Belgium , Cadiz, Spain , Coimbra, Portugal , Cologne, Germany and 28 more locations